Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05118841
Other study ID # ZX-4081
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date January 3, 2022
Est. completion date May 2024

Study information

Verified date January 2022
Source Nanjing Zenshine Pharmaceuticals
Contact Xiaoli Qin, PhD
Phone (+1) 650-799-2796
Email xiaoli.qin@zenshine-pharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 1, first-in-human, open-label, multicenter, dose escalation and dose expansion study to investigate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of ZX-4081 administered orally (PO) twice daily (BID) in 28-day cycles in patients with Advanced Solid Tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date May 2024
Est. primary completion date May 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Metastatic or locally advanced solid tumor malignancies (breast cancer, urothelial cancer, ovarian cancer, melanoma, NSCLC, renal cell carcinoma, squamous cell cancer of the head and neck, colorectal cancer, and hepatocellular carcinoma) that has progressed on, is refractory to, intolerant to, or for which there is no curative standard of care therapy. 2. Measurable disease with at least 1 lesion amenable to response assessment per RECIST 1.1. 3. Demonstrate adequate organ function. All screening laboratories should be performed within 14 days of treatment initiation. 4. Has a performance status of 0-2 on the ECOG Performance Scale. 5. Life expectancy >12 weeks at baseline. 6. Women of childbearing potential must have negative serum or urine pregnancy test within 72 hours prior to receiving the first study drug administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Women of childbearing potential must be willing to use an adequate method of contraception from 30 days prior to the first study drug administration and 120 days following last day study drug administration. 7. Male patients of childbearing potential must be surgically sterile, or must agree to use adequate method of contraception during the study and at least 120 days following the last day of study drug administration. 8. Age =18 years at screening. 9. Able and willing to provide written informed consent and to follow study instructions. Exclusion Criteria: 1. Patient has disease that is suitable for therapy administered with curative intent. 2. Untreated or uncontrolled central nervous system (CNS) involvement. 3. Any concurrent or recent use (within 28 days or 5 half-lives, whichever is longer) of chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment. 4. Unresolved toxicities from prior therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, with exception of alopecia and vitiligo. 5. Systemic corticosteroids at doses exceeding 10 mg/day prednisone or equivalent. 6. Patient has an active infection requiring systemic therapy. 7. Patients who have known active HIV, Hepatitis or active COVID-19 infection. (Patients who have been vaccinated against Hepatitis B and who are positive only for the Hepatitis B surface antibody are permitted to participate in the study). Patients who are positive for hepatitis B or C virus must be tested for and have an undetectable viral load. 8. Patients with unstable/inadequate cardiac function: 1. New York Heart Association Class 3 or 4 congestive heart failure, 2. Uncontrolled hypertension, 3. Acute coronary syndrome within 6 months, 4. Clinical important cardiac arrhythmia, 5. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >470 milliseconds (ms) (CTCAE grade 1) using Fredericia's QT correction formula. 9. A history of additional risk factors for Torsades de Pointes(TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome). 10. The use of concomitant medications that prolong the QT/QTc interval. 11. Concomitant use or recent use (at least 2 weeks before the start of ZX-4081 treatment) of drugs that are known to be strong CYP3A4/5 inhibitors and CYP3A4/5 inducers (See 5.4.2 for a list of study medications not allowed during this study). 12. Concomitant use of drugs that are sensitive substrates with narrow therapeutic index for one of the following: CYP2C9, CYP2C19, CYP2C8, CYP2D6 and CYP3A4 (See 5.4.2 for a list of study medications not allowed during this study). 13. Concomitant use of drugs that are sensitive substrates with narrow therapeutic index for one of the following transporters: P-glycoprotein (P-gp) and Breast Cancer resistance Protein (BCRP). 14. Recent use a proton pump inhibitor (within 4 days prior to the start ZX-4081 treatment) or a histamine H2 blocker (within 2 days prior to the start of ZX-4081 treatment). 15. Uncontrolled concurrent illness. 16. Patient has concurrent active malignancy other than nonmelanoma skin cancer, carcinoma in situ of the cervix, or superficial bladder cancer who has undergone potentially curative therapy with no evidence of disease. Patients with other previous malignancies are eligible if disease-free for >2 years. 17. Participation in another clinical trial of an investigational agent within 30 days of screening. 18. Patient has known psychiatric, substance abuse or other disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the investigator. 19. Patients who are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of trial treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ZX-4081
Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle

Locations

Country Name City State
United States Carolina BioOncology Huntersville North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Nanjing Zenshine Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the recommended Phase 2 dose (RP2D) of ZX-4081 To assess number of patients experiencing dose-limiting toxicities (DLTs) in the dose escalation phase At the end of Cycle 1 (each cycle is 28 days)
Primary Safety and tolerability of ZX-4081 To examine the incidence of clinical and laboratory adverse events after multiple doses of ZX-4081 in the dose escalation and dose expansion phases From first dose of ZX-4081 through 28 days after the last ZX-4081 treatment (up to 2 years); each cycle is 28 days
Secondary Peak Plasma Concentration of ZX-4081 To evaluate the maximum observed concentration (Cmax) after single and repeated oral, twice daily (BID) doses of ZX-4081 Days 1, 8, and 15 of Cycle 1 (each cycle is 28 days)
Secondary Area under the plasma concentration of ZX-4081 To evaluate the area under the curve (AUC) plasma-concentration after single and repeated oral, BID doses of ZX-4081 Days 1, 8, and 15 of Cycle 1 (each cycle is 28 days)
Secondary Half-life of ZX-4081 To evaluate the half-life of ZX-4081 after single and repeated oral, BID doses of ZX-4081 Days 1, 8, and 15 of Cycle 1 (each cycle is 28 days)
Secondary Objective response rate (ORR) To evaluate the objective response rate (ORR) as determined by the specific disease response criteria Up to 2 years
Secondary Duration of Response (DOR) To examine the duration of response (DoR), defined as time from the date of first documentation of response to the date of the first documentation of progressive disease (PD), or death due to any cause Up to 2 years
Secondary Progression Free Survival (PFS) To examine the the progression free survival (PFS), defined as time from the date of first dose of study treatment to the first date of documentation of PD, or death due to any cause Up to 2 years
Secondary Overall Survival (OS) To examine the overall survival (OS), defined as time from the date of first dose of study treatment to death due to any cause Up to 2 years
Secondary Peripheral myeloid-derived suppressor cell (MDSC) proportion in the blood To assess the changes of peripheral MDSC proportion in the blood after single and repeated oral, BID doses of ZX-4081 Cycle 1 Day1 , Cycle 2 Day 1, and Cycle 3 Day 1 (each cycle is 28 days)
Secondary T cell composition and activation status To assess the impact on T cell profiles after repeated oral, BID doses of ZX-4081 Cycle 1 Day1 , Cycle 2 Day 1, and Cycle 3 Day 1 (each cycle is 28 days)
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05508100 - Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors Phase 1
Not yet recruiting NCT05515185 - B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors Early Phase 1
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06007482 - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Recruiting NCT05076396 - PM14 Administered Intravenously to Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06008366 - A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06054932 - Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors Phase 1
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05569057 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT05461287 - Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05443126 - A Study of EP0031 in Patients With Advanced RET-altered Malignancies Phase 1/Phase 2
Recruiting NCT04592653 - Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) Phase 1/Phase 2